Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Cascadian Therapeutics, Inc. | d47758dex321.htm |
| 10-Q - 10-Q - Cascadian Therapeutics, Inc. | d47758d10q.htm |
| EX-31.2 - EX-31.2 - Cascadian Therapeutics, Inc. | d47758dex312.htm |
| EX-10.1 - EX-10.1 - Cascadian Therapeutics, Inc. | d47758dex101.htm |
| EX-31.1 - EX-31.1 - Cascadian Therapeutics, Inc. | d47758dex311.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)
I, Julia M. Eastland, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Oncothyreon Inc. for the quarterly period ended September 30, 2015, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Oncothyreon Inc.
| November 5, 2015 | /s/ Julia M. Eastland | |
| Julia M. Eastland | ||
| Chief Financial Officer, Secretary and Vice President of Corporate Development | ||
| (Principal Financial and Accounting Officer) |